BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-0866-2018

AuroMedics Pharma LLC · East Windsor, NJ

Class I — life-threatening Terminated 2381 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

Ampicillin and Sulbactam for Injection, USP, 3 gram*s/vial, For Intramuscular or Intravenous Use, Sterile, Manufactured for: AuroMedics Pharma LLC, 6 Wheeling Road, Dayton, NJ, NDC 55150-117-20.

Lot / code: Lot #: AS0317041-A, AS0317035-A; Exp August 2019

Quantity: 54,720 vials

Reason for recall

Presence of Particulate Matter: confirmed customer report of the presence of visible particulate matter believed to be red rubber particles from the manufacturing process of the active ingredients.

Recall record

Recall number
D-0866-2018
Classification
Class I
Status
Terminated
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Letter
Distribution
Nationwide in the USA and Puerto Rico
Recall initiated
2018-05-01
Classified by FDA Center
2018-06-14
FDA published
2018-05-16
Terminated
2024-11-06
Recalling firm
AuroMedics Pharma LLC
Firm location
East Windsor, NJ

Drug identification

Brand name(s)
AMPICILLIN AND SULBACTAM
Generic name(s)
AMPICILLIN SODIUM AND SULBACTAM SODIUM
Manufacturer(s)
Eugia US LLC
NDC(s)
55150-116, 55150-117, 55150-178, 55150-179
Route(s)
INTRAMUSCULAR, INTRAVENOUS

‹ All recalls